Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial

被引:82
|
作者
Ahn, Jiyoung [1 ]
Albanes, Demetrius [1 ]
Peters, Ulrike [2 ]
Schatzkin, Arthur [1 ]
Lim, Unhee [1 ]
Freedman, Michal [1 ]
Chatterjee, Nilanjan [1 ]
Andriole, Gerald L. [3 ]
Leitzmann, Michael F. [1 ]
Hayes, Richard B. [1 ]
机构
[1] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[2] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Fred Hutchinson Canc Res Ctr,Canc Prevent Program, Seattle, WA 98195 USA
[3] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA
关键词
D O I
10.1158/1055-9965.EPI-07-0601
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Higher intakes of calcium and dairy products, a major source of dietary calcium, are reported to increase the risk of prostate cancer, potentially due to reductions in circulating vitamin D with increasing calcium intake. We prospectively examined the association of dairy product and calcium intake with prostate cancer risk in 29,509 men, including 1,910 cases, in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. We also evaluated the relation of calcium intake with serum 25-hydroxy-vitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)(2)D], in a Prostate, Lung, Colorectal, and Ovarian Trial substudy (n = 275). Dietary intake was assessed using a food frequency questionnaire. Baseline serum 1,25(OH)2D was determined by RIA. Greater intake of dairy products, particularly low-fat dairy products, was weakly associated with increased risk of prostate cancer [relative risk (RR), 1.12; 95% confidence intervals (CI), 0.97-1.30; P trend = 0.06 for >2.75 versus <= 0.98 servings of total dairy/day; 1.23 (1.07-1.41) for low-fat dairy]. Greater dietary calcium intake was associated with increased risk of prostate cancer (RR, 1.34; 95% CI, 0.93-1.94; P trend = 0.02 for >2,000 versus <1,000 mg/day), but greater supplementary calcium intake was not associated with the risk. Associations of dairy product and dietary calcium intake were evident for nonaggressive disease (RR, 1.20; 95% CI, 0.99-1.46; P trend = 0.01 for dairy products; 1.64, 1.04-2.57; P trend = 0.002 for dietary calcium), but not aggressive disease (RR, 1.02; 95% CI, 0.81-1.28 for dairy products; 0.94, 0.49-1.80 for dietary calcium). Calcium intake was not associated with serum 25-hydroxyvitamin D and 1,25(OH)(2)D concentration. In this large prospective study in a prostate cancer screening trial, greater dietary intake of calcium and dairy products, particularly low-fat types, may be modestly associated with increased risks for nonaggressive prostate cancer, but was unrelated to aggressive disease. Furthermore, we found no relationship between calcium intake and circulating vitamin D.
引用
收藏
页码:2623 / 2630
页数:8
相关论文
共 50 条
  • [21] Calcium to magnesium intake ratio and colorectal carcinogenesis, results from the Prostate, Lung, Colorectal, and Ovarian cancer screening trial
    Zhao, Jing
    Zhu, Xiangzhu
    Shrubsole, Martha J.
    Edwards, Todd L.
    Giovannucci, Edward L.
    Zheng, Wei
    Dai, Qi
    [J]. CANCER RESEARCH, 2016, 76
  • [22] Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial
    Zhao, Jing
    Giri, Ayush
    Zhu, Xiangzhu
    Shrubsole, Martha J.
    Jiang, Yixing
    Guo, Xingyi
    Ness, Reid
    Seidner, Douglas L.
    Giovannucci, Edward
    Edwards, Todd L.
    Dai, Qi
    [J]. BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 796 - 804
  • [23] Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Koutros, Stella
    Meyer, Tamra E.
    Fox, Stephen D.
    Issaq, Haleem J.
    Veenstra, Timothy D.
    Huang, Wen-Yi
    Yu, Kai
    Albanes, Demetrius
    Chu, Lisa W.
    Andriole, Gerald
    Hoover, Robert N.
    Hsing, Ann W.
    Berndt, Sonja I.
    [J]. CARCINOGENESIS, 2013, 34 (10) : 2281 - 2285
  • [24] Dietary consumption of tea and the risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Thomas, Robert J.
    McConnachie, Alex
    Stanley, Bethany
    Williams, Madeleine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Stolzenberg-Solomon, RZ
    Chang, SC
    Leitzmann, MF
    Johnson, KA
    Johnson, C
    Buys, SS
    Hoover, RN
    Ziegler, RG
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 83 (04): : 895 - 904
  • [26] Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    L M Ferrucci
    A J Cross
    B I Graubard
    L A Brinton
    C A McCarty
    R G Ziegler
    X Ma
    S T Mayne
    R Sinha
    [J]. British Journal of Cancer, 2009, 101 : 178 - 184
  • [27] Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Ferrucci, L. M.
    Cross, A. J.
    Graubard, B. I.
    Brinton, L. A.
    McCarty, C. A.
    Ziegler, R. G.
    Ma, X.
    Mayne, S. T.
    Sinha, R.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 101 (01) : 178 - 184
  • [28] Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial
    Pinsky, Paul F.
    Crawford, E. David
    Kramer, Barnett S.
    Andriole, Gerald L.
    Gelmann, Edward P.
    Grubb, Robert
    Greenlee, Robert
    Gohagan, John K.
    [J]. BJU INTERNATIONAL, 2007, 99 (04) : 775 - 779
  • [29] Obesity and prostate cancer screening, incidence, and mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Hurwitz, Lauren M.
    Dogbe, Nadine
    Barry, Kathryn Hughes
    Koutros, Stella
    Berndt, Sonja, I
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (12): : 1506 - 1514
  • [30] Lung Cancer Risk Prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Models and Validation
    Tammemagi, C. Martin
    Pinsky, Paul F.
    Caporaso, Neil E.
    Kvale, Paul A.
    Hocking, William G.
    Church, Timothy R.
    Riley, Thomas L.
    Commins, John
    Oken, Martin M.
    Berg, Christine D.
    Prorok, Philip C.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (13) : 1058 - 1068